Well, a $1 billion acquisition, not so unusual in the life sciences industry arena...
…but, in fact, quite rare!
Let's consider this: a Phase II candidate… in an "ultra-rare" indication, Hypophosphatasia (< 1/100.000 prevalence according to Orphanet).. $1 billion... the largest, largest ever deal in orphan diseases.. for a single drug candidate.
Humm…this is all good BUT what if the actual driver in this acquisition is in fact a far larger, blockbuster-type underlying indication such as…osteoporosis?
Well, just an idea!
Websites:
